CEFUROXIME SODIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cefuroxime Sodium, and what generic alternatives are available?
Cefuroxime Sodium is a drug marketed by Acs Dobfar Spa, Fresenius Kabi Usa, Hikma, Hospira Inc, Teva Pharms, Watson Labs Inc, and Samson Medcl. and is included in fourteen NDAs.
The generic ingredient in CEFUROXIME SODIUM is cefuroxime sodium. There are sixty-two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the cefuroxime sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cefuroxime Sodium
A generic version of CEFUROXIME SODIUM was approved as cefuroxime sodium by ACS DOBFAR SPA on May 30th, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CEFUROXIME SODIUM?
- What are the global sales for CEFUROXIME SODIUM?
- What is Average Wholesale Price for CEFUROXIME SODIUM?
Summary for CEFUROXIME SODIUM
| US Patents: | 0 |
| Applicants: | 7 |
| NDAs: | 14 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 104 |
| Clinical Trials: | 3 |
| Patent Applications: | 916 |
| DailyMed Link: | CEFUROXIME SODIUM at DailyMed |
Recent Clinical Trials for CEFUROXIME SODIUM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Hospital Universitari Vall d'Hebron Research Institute | Phase 4 |
| University Hospital, Basel, Switzerland | Phase 4 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2/Phase 3 |
Pharmacology for CEFUROXIME SODIUM
| Drug Class | Cephalosporin Antibacterial |
Anatomical Therapeutic Chemical (ATC) Classes for CEFUROXIME SODIUM
US Patents and Regulatory Information for CEFUROXIME SODIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acs Dobfar Spa | CEFUROXIME SODIUM | cefuroxime sodium | INJECTABLE;INJECTION | 064125-002 | May 30, 1997 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teva Pharms | CEFUROXIME SODIUM | cefuroxime sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 064192-002 | Apr 16, 1998 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hospira Inc | CEFUROXIME SODIUM | cefuroxime sodium | INJECTABLE;INJECTION | 065483-002 | Oct 15, 2008 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Fresenius Kabi Usa | CEFUROXIME SODIUM | cefuroxime sodium | INJECTABLE;INJECTION | 065002-001 | Sep 28, 1998 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Watson Labs Inc | CEFUROXIME SODIUM | cefuroxime sodium | INJECTABLE;INJECTION | 064036-001 | Feb 26, 1993 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
